Study of a pill to raise low platelets after chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a solid tumor cancer (like lung, breast, ovarian, bladder, pancreatic, or colon cancer).
- You must be receiving chemotherapy that includes a platinum drug or gemcitabine, given in 21-day cycles.
- You should be able to care for yourself (ECOG score 0–2) and have a life expectancy of 6 months or more.
- Your low platelet count must be caused by chemotherapy — not by other conditions like liver disease, an enlarged spleen, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
This trial tests a drug called hetrombopag that helps raise platelet counts in people with nasopharyngeal cancer who get low platelets from their chemotherapy. It may reduce the need for platelet transfusions and help you stay on your chemo schedule.
Hear when a new Patients With Chemotherapy-Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.